Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia

PLoS One. 2022 Mar 31;17(3):e0266090. doi: 10.1371/journal.pone.0266090. eCollection 2022.

Abstract

We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs) to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using bioinformatics tools, we selected a 12-mer tract of the CD5 mRNA as the molecular target and synthesized the complementary and control PNA strands bearing a serine phosphate dipeptide tail to enhance their water solubility and bioavailability. The specific recognition of the 12-mer DNA strand, corresponding to the target mRNA sequence by the complementary PNA strand, was confirmed by non-denaturing polyacrylamide gel electrophoresis, thermal difference spectroscopy, circular dichroism (CD), and CD melting studies. Cytofluorimetric assays and real-time PCR analysis demonstrated the downregulation of CD5 expression due to incubation with the anti-CD5 PNA at RNA and protein levels in Jurkat cell line and peripheral blood mononuclear cells from B-CLL patients. Interestingly, we also observed that transfection with the anti-CD5 PNA increases apoptotic response induced by fludarabine in B-CLL cells. The herein reported results suggest that PNAs could represent a potential candidate for the development of antisense therapeutic agents in CLL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Leukocytes, Mononuclear
  • Oligonucleotides, Antisense / genetics
  • Oligonucleotides, Antisense / pharmacology
  • Peptide Nucleic Acids* / chemistry
  • RNA, Messenger / genetics

Substances

  • Oligonucleotides, Antisense
  • Peptide Nucleic Acids
  • RNA, Messenger

Grants and funding

NB, GP, and GO acknowledges funding support from Ministero dell’Università e della Ricerca FOE 2017 - ISBE-IT Joint Research Unit. GO received funds from Regione Campania POR FESR 2014/2020 within the project “Biochip per la diagnosi rapida ed il follow-up della leucemia linfatica cronica nella popolazione in territorio a rischio” (project N. B63D18000250007). NB and GP received funds from Regione Campania POR FESR 2014/2020 within the project “Combattere la resistenza tumorale: piattaforma integrata multidisciplinare per un approccio tecnologico innovativo alle oncoterapie-Campania Oncoterapie” (Project N. B61G18000470007). MG received funds from Regione Campania “SATIN” grant 2018-2020.